Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 3NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Pain 1Musculoskeletal Pain 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Cyclophosphamide 39Docetaxel 30Tamoxifen 29Paclitaxel 27Doxorubicin 26Trastuzumab 20Radiotherapy 18Epirubicin 16Letrozole 13exemestane 11Fluorouracil 11Anastrozole 11Capecitabine 10Bevacizumab 10Immunohistochemistry 9Filgrastim 9Fulvestrant 8Methotrexate 7Gene Expression Profiling 7palbociclib 6Zoledronic Acid 6Microarray Analysis 6Lapatinib 6Goserelin 6Chemotherapy, Adjuvant 6Amplified Fragment Length Polymorphism Analysis 6Vinorelbine 5Triptorelin Pamoate 5Carboplatin 5Absorptiometry, Photon 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Breast Neoplasms × Duloxetine Hydrochloride × Clear all
NCT06407401 2024-11-05

Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Not yet recruiting
399 enrolled
Breast

Breast Neoplasms, Musculoskeletal Pain, Drug-Related Side Effects and Adverse Reactions

NCT01598298 2022-12-16

S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

SWOG Cancer Research Network

Phase 3 Completed
299 enrolled 10 charts
Breast

Breast Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡